Archived Monthly Oncology Tumor Boards: Diagnosis and Management of Marginal Zone Lymphomas
Marginal zone lymphomas (MZLs) represent a clinical challenge due to their heterogeneity, and the relative rarity of individual subtypes has largely precluded the use of standard treatment approach across all subtypes. Educating clinicians about the biology of MZLs, novel therapeutic approaches, and special considerations will help them to develop an individualized treatment plan to optimize clinical outcomes.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: Update on New Treatments for Biliary Tract Cancers
While relatively rare, biliary tract cancers have a poor prognosis. Recently, molecular profiling has become increasingly useful as some new targeted therapies received FDA approval. It is important for clinicians to keep abreast of new and upcoming therapies in order to develop an optimal treatment strategy.
Category
  • Hepatobiliary Cancers
  • Hepatocellular Carcinoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: New Targeted Therapies for Non-Small Cell Lung Cancer
This tumor board will discuss how to select the most appropriate therapy for patients with non-small cell lung cancer (NSCLC) using a case-based format. New targeted therapy regimens are being rapidly approved for patients with metastatic NSCLC and have been shown to improve outcomes for these patients.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Monthly Oncology Tumor Boards: Management of Non-Metastatic Prostate Cancer
Clinicians need to be knowledgeable about newer tools that can improve risk stratification, and they need to understand when these tools have the possibility to change management so that unnecessary testing can be avoided. In addition, clinicians should be educated about the heterogeneity among risk groups, so that nuanced discussions with patients can inform decisions surrounding active surveillance.
Category
  • Prostate Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date July 6, 2022
Monthly Oncology Tumor Boards: Management of Well-Differentiated Grade 3 Neuroendocrine Tumors
It is important to inform clinicians about this new section of the NCCN Guidelines for Neuroendocrine and Adrenal Tumors, which include recommendations for the evaluation, management, and surveillance of well-differentiated G3 NETs. Keeping clinicians abreast of updated treatment options may help improve clinical decision-making to better address patients’ medical needs.
Category
  • Neuroendocrine Tumors
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date June 23, 2022

Pages